Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand

Human Gene Therapy

Volumn 10, Issue 10, 1999, Pages 1641-1648

  Ambar, Benjamin B ^a   Frei, Karl ^a   Malipiero, Ursula ^a   Morelli, Adrian E ^b   Castro, Maria G ^b   Lowenstein, Pedro R ^b   Fontana, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYTOKINE; FAS LIGAND; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE THERAPY; GLIOMA; GLIOMA CELL; IMMUNOHISTOCHEMISTRY; MALE; NATURAL KILLER CELL; NONHUMAN; RAT; SURVIVAL TIME; T LYMPHOCYTE; TARGET CELL;

ADENOVIRUSES, HUMAN; ANIMALS; DRUG RESISTANCE; FAS LIGAND PROTEIN; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 0033166087     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017644     Document Type: Article

References (28)

1. ARAI, H., GORDON, D., NABEL, E.G., and NABEL, G.J. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U.S.A. 94, 13862-13867.
2. BARTH, R.F. (1998). Rat brain tumor models in experimental neurooncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol. 36, 91-102.
3. FONTANA, A., HENGARTNER, H., DE TRIBOLET, N., and WEBER, E. (1984). Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol. 132, 1837-1844.
4. FONTANA, A., FREI, K., BODMER, S., HOFER, E., SCHREIER, M.H., PALLADINO, M.A., JR., and ZINKERNAGEL, R.M. (1989). Transforming growth factor-β inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 143, 3230-3234.
5. FREI, K., AMBAR, B.B., ADACHI, N., YONEKAWA, Y., and FONTANA, A. (1998). Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. J. Neuroimmunol. 87, 105-113.
6. FRENCH, L.E., and TSCHOPP, J. (1996). Constitutive Fas ligand expression in several nonlymphoid mouse tissues: Implications for immune-protection and cell turnover. Behring Inst. Mitt. 97, 156-160.
7. GRATAS, C., TOHMA, Y., VAN MEIR, E.G., KLEIN, M., TENAN, M., ISHII, N., TACHIBANA, O., KLEIHUES, P., and OHGAKI, H. (1997). Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7, 863-869.
8. HUSAIN, N., CHIOCCA, E.A., RAINOV, N., LOUIS, D.N., and ZERVAS, N.T. (1998). Coexpression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. (Berlin) 95, 287-290.
9. KO, L., KOESTNER, A., and WECHSLER, W. (1980). Characterization of cell cycle and biological parameters of transplantation glioma cell lines clones. Acta Neuropathol. (Berlin) 51, 107-111.
10. KOBAYASHI, N., ALLEN, N., CLENDENON, N.R., and KO, L.-W. (1980). An improved rat brain-tumor model. J. Neurosurg 53, 808-815.
11. LAU, H.T., YU, M., FONTANA, A., and STOECKERT, C.J., JR. (1996). Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112.
12. LOWENSTEIN, P.R., SHERING, A.F., BAIN, D., CASTRO, M.G., and WILKINSON, G.W.G. (1996). The use of adenovirus vectors to transfer genes to identified target brain cells in vitro. In Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. P.R. Lowenstein and L.W. Enquist, eds. (John Wiley & Sons, Chichester, UK) pp. 93-114.
13. MALIPIERO, U., FREI, K., SPANAUS, K.S., AGRESTI, C., LASSMANN, H., HAHNE, M., TSCHOPP, J., EUGSTER, H.P., and FONTANA, A. (1997). Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perform knockout mice, but monophasic in Fas-and Fas ligand-deficient lpr and gld mice. Eur. J. Immunol. 27, 3151-3160.
14. MORELLI, A.E., LARREGINA, A.T., SMITH-ARICA, J., DEWEY, R.A., SOUTHGATE, T.D., AMBAR, B., FONTANA, A., CASTRO, M.G., and LOWENSTEIN, P.R. (1999). Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J. Gen. Virol. 80, 571-583.
15. NAGATA, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
16. RENSING, EHL, A., FREI, K., FLURY, R., MATIBA, B., MARIANI, S.M., WELLER, M., AEBISCHER, P., KRAMMER, P.H., and FONTANA, A. (1995). Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258.
17. RENSING-EHL, A., MALIPIERO, U., IRMLER, M., TSCHOPP, J., CONSTAM, D., and FONTANA, A. (1996). Neurons induced to express major histocompatibility complex class I antigen are killed via the perform and not the Fas (APO-1/CD95) pathway. Eur. J. Immunol. 26, 2271-2274.
18. SAAS, P., WALKER, P.R., HAHNE, M., QUIQUEREZ, A.-L., SCHNURIGER, V., PERRIN, G., FRENCH, L., VAN MEIER, E.G., DE TRIBOLET, N., TSCHOPP, J., and DIETRICH P.-Y. (1997). Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99, 1173-1178.
19. SCHNEIDER, P., HOLLER, N., BODMER, J.L., HAHNE, M., FREI, K., FONTANA, A., and TSCHOPP, J. (1998). Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213.
20. SHERING, A.F., BAIN, D., STEWART, K., EPSTEIN, A.L., CASTRO, M.G., WILKINSON, G.W., and LOWENSTEIN, P.R. (1997). Cell-type specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J. Gen. Virol. 78, 445-449.
21. SPANAUS, K.S., SCHLAPBACH, R., and FONTANA, A. (1998). TNF-α and IFN-γ render microglia sensitive to Fas lignad-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Eur. J. Immunol. 28, 4398-4408.
22. TACHIBANA, O., LAMPE, J., KLEIHUES, P., and OHGAKI, H. (1996). Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol. (Berlin) 92, 431-434.
23. TANAKA, M., SUDA, T., TAKAHASHI, T., and NAGATA, S. (1995). Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
24. TRAUTH, B.C., KLAS, C., PETERS, A.M., MATZKU, S., MOLLER, P., FALK, W., DEBATIN, K.M., and KRAMMER, P.H. (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305.
25. TZENG, J.-J., BARTH, R.F., CLENDENON, N.R., and GORDON, W.A. (1990). Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50, 4338-4343.
26. WALCZAK, H., MILLER, R.E., ARIAL, K., GLINIAK, B., GRIFFITH, T.S., KUBIN, M., CHIN, W., JONES, J., WOODWARD, A., LE, T., SMITH, C., SMOLAK, P., GOODWIN, R.G., RAUCH, C.T., SCHUH, J.C.L., and LYNCH, D.H. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157-163.
27. WELLER, M., FREI, K., GROSCURTH, P., KRAMMER, P.H., YONEKAWA, Y., and FONTANA, A. (1994). Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94, 954-964.
28. WRANN, M., BODMER, S., DE MARTIN, R., SIEPL, C., HOFER-WARBINEK, R., FREI, K., HOFER, E., and FONTANA, A. (1987). T cell suppressor factor from human glioblastoma cells is a 12.5-kD protein closely related to transforming growth factor-β. EMBO J. 6, 1633-1636.